Holen Sie sich die Stockscreener-App
5.65
5.81%
0.31
Handel nachbörslich:
5.61
-0.04
-0.71%
Schlusskurs vom Vortag:
$5.34
Offen:
$5.36
24-Stunden-Volumen:
35,753
Relative Volume:
0.41
Marktkapitalisierung:
$2.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+14.60%
1M Leistung:
+21.77%
6M Leistung:
-65.92%
1J Leistung:
-96.83%
1-Tages-Spanne:
$5.12
$5.65
1-Wochen-Bereich:
$4.91
$5.65
52-Wochen-Spanne:
$2.9218
$699.19
Psyence Biomedical Ltd Stock (PBM) Company Profile
Firmenname
Psyence Biomedical Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PBM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBM
Psyence Biomedical Ltd
|
5.65 | 2.90M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Psyence Biomedical Ltd Aktie (PBM) Neueste Nachrichten
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 - TradingView
Psychedelic Industry Summit: Top CEOs and Investors Unite to Shape $Billion Market Future - Stock Titan
Psyence Biomedical regains Nasdaq compliance after reverse split By Investing.com - Investing.com Nigeria
Psyence Biomedical regains Nasdaq compliance after reverse split - Investing.com
Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements - Newsfile
Psyence Biomedical (NASDAQ:PBM) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Psyence Biomedical Advances Psilocybin Trial with New CRO Agreement - TipRanks
Psyence Biomedical Ltd. (NASDAQ:PBM) Short Interest Up 55.3% in May - Defense World
Psyence BioMed advances Phase IIb psilocybin trial with new CRO partnershi By Investing.com - Investing.com South Africa
Psyence BioMed advances Phase IIb psilocybin trial with new CRO partnershi - Investing.com Australia
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial - TradingView
FDA Backs Psyence BioMed's Groundbreaking Phase IIb Psilocybin Trial for Cancer Mental Health - Stock Titan
Psyence Biomedical (NASDAQ:PBM) Shares Down 0.7% – Should You Sell? - Defense World
Psyence Biomedical Advances Psilocybin Drug Development as of May 2025 - TipRanks
Reviewing Psyence Biomedical (NASDAQ:PBM) and Immunic (NASDAQ:IMUX) - Defense World
Psyence Biomedical announces reverse stock split - Investing.com
Psyence Biomedical announces reverse stock split By Investing.com - Investing.com Nigeria
Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split - Newsfile
Psyence BioMed Reverse Split Cuts 4.6M Shares to 583K: What Investors Must Know Before May 5 - Stock Titan
Psyence Biomedical Faces Nasdaq Delisting Amid Shareholder Approval for Reverse Stock Split - TipRanks
Psyence BioMed gets Nasdaq notice for non-compliance - MSN
Psyence Group consolidates its shares - Crain's Chicago Business
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - TradingView
Psyence BioMed Under Nasdaq Delisting Pressure: Key Details About the 1:7.97 Reverse Split Solution - Stock Titan
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine
Psyence BioMed boosts stake in PsyLabs with $500k investment By Investing.com - Investing.com Nigeria
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement - Newsfile
Psyence Biomedical Transitions CRO for Psilocybin Trial in April 2025 - TipRanks
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia - Newsfile
Major Expansion: Psyence's Breakthrough Cancer Mental Health Trial Targets Untreated Disorder - Stock Titan
Psyence Biomedical reports corporate update By Investing.com - Investing.com Australia
Psyence Biomedical reports corporate update - Investing.com
Psyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical Trials - TipRanks
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing - TradingView
Psyence Biomedical Announces Special Shareholder Meeting for Share Consolidation - TipRanks
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein - The Manila Times
Psyence Biomedical Ltd. (NASDAQ:PBMWW) Short Interest Down 13.1% in February - Defense World
Psyence Biomed expands advisory board with psychopharmacology expert By Investing.com - Investing.com Australia
Psyence Biomed expands advisory board with psychopharmacology expert - Investing.com India
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein - Newsfile
Top Columbia Psychiatrist Joins Psyence's Psilocybin Clinical Trial Team - StockTitan
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - The Manila Times
Finanzdaten der Psyence Biomedical Ltd-Aktie (PBM)
Es liegen keine Finanzdaten für Psyence Biomedical Ltd (PBM) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):